Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.
Adult
Age Factors
Aged
Alzheimer Disease
/ pathology
Blood Pressure
/ physiology
Brain
/ pathology
Cohort Studies
Epidemiologic Studies
Female
Humans
Hypertension
/ complications
Image Interpretation, Computer-Assisted
Magnetic Resonance Imaging
Male
Middle Aged
Organ Size
/ physiology
Positron-Emission Tomography
Risk Factors
United Kingdom
Young Adult
Journal
The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
01
02
2019
revised:
08
05
2019
accepted:
09
05
2019
pubmed:
25
8
2019
medline:
9
6
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with late-life brain structure, pathology, and cognition. Participants were from Insight 46, a neuroscience substudy of the ongoing longitudinal Medical Research Council National Survey of Health and Development, a birth cohort that initially comprised 5362 individuals born throughout mainland Britain in one week in 1946. Participants aged 69-71 years received T1 and FLAIR volumetric MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University College London (London, UK); all participants were dementia-free. Blood pressure measurements had been collected at ages 36, 43, 53, 60-64, and 69 years. We also calculated blood pressure change variables between ages. Primary outcome measures were white matter hyperintensity volume (WMHV) quantified from multimodal MRI using an automated method, amyloid-β positivity or negativity using a standardised uptake value ratio approach, whole-brain and hippocampal volumes quantified from 3D-T1 MRI, and a composite cognitive score-the Preclinical Alzheimer Cognitive Composite (PACC). We investigated associations between blood pressure and blood pressure changes at and between 36, 43, 53, 60-64, and 69 years of age with WMHV using generalised linear models with a gamma distribution and log link function, amyloid-β status using logistic regression, whole-brain volume and hippocampal volumes using linear regression, and PACC score using linear regression, with adjustment for potential confounders. Between May 28, 2015, and Jan 10, 2018, 502 individuals were assessed as part of Insight 46. 465 participants (238 [51%] men; mean age 70·7 years [SD 0·7]; 83 [18%] amyloid-β-positive) were included in imaging analyses. Higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) at age 53 years and greater increases in SBP and DBP between 43 and 53 years were positively associated with WMHV at 69-71 years of age (increase in mean WMHV per 10 mm Hg greater SBP 7%, 95% CI 1-14, p=0·024; increase in mean WMHV per 10 mm Hg greater DBP 15%, 4-27, p=0·0057; increase in mean WMHV per one SD change in SBP 15%, 3-29, p=0·012; increase in mean WMHV per 1 SD change in DBP 15%, 3-30, p=0·017). Higher DBP at 43 years of age was associated with smaller whole-brain volume at 69-71 years of age (-6·9 mL per 10 mm Hg greater DBP, -11·9 to -1·9, p=0·0068), as were greater increases in DBP between 36 and 43 years of age (-6·5 mL per 1 SD change, -11·1 to -1·9, p=0·0054). Greater increases in SBP between 36 and 43 years of age were associated with smaller hippocampal volumes at 69-71 years of age (-0·03 mL per 1 SD change, -0·06 to -0·001, p=0·043). Neither absolute blood pressure nor change in blood pressure predicted amyloid-β status or PACC score at 69-71 years of age. High and increasing blood pressure from early adulthood into midlife seems to be associated with increased WMHV and smaller brain volumes at 69-71 years of age. We found no evidence that blood pressure affected cognition or cerebral amyloid-β load at this age. Blood pressure monitoring and interventions might need to start around 40 years of age to maximise late-life brain health. Alzheimer's Research UK, Medical Research Council, Dementias Platform UK, Wellcome Trust, Brain Research UK, Wolfson Foundation, Weston Brain Institute, Avid Radiopharmaceuticals.
Sections du résumé
BACKGROUND
Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with late-life brain structure, pathology, and cognition.
METHODS
Participants were from Insight 46, a neuroscience substudy of the ongoing longitudinal Medical Research Council National Survey of Health and Development, a birth cohort that initially comprised 5362 individuals born throughout mainland Britain in one week in 1946. Participants aged 69-71 years received T1 and FLAIR volumetric MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University College London (London, UK); all participants were dementia-free. Blood pressure measurements had been collected at ages 36, 43, 53, 60-64, and 69 years. We also calculated blood pressure change variables between ages. Primary outcome measures were white matter hyperintensity volume (WMHV) quantified from multimodal MRI using an automated method, amyloid-β positivity or negativity using a standardised uptake value ratio approach, whole-brain and hippocampal volumes quantified from 3D-T1 MRI, and a composite cognitive score-the Preclinical Alzheimer Cognitive Composite (PACC). We investigated associations between blood pressure and blood pressure changes at and between 36, 43, 53, 60-64, and 69 years of age with WMHV using generalised linear models with a gamma distribution and log link function, amyloid-β status using logistic regression, whole-brain volume and hippocampal volumes using linear regression, and PACC score using linear regression, with adjustment for potential confounders.
FINDINGS
Between May 28, 2015, and Jan 10, 2018, 502 individuals were assessed as part of Insight 46. 465 participants (238 [51%] men; mean age 70·7 years [SD 0·7]; 83 [18%] amyloid-β-positive) were included in imaging analyses. Higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) at age 53 years and greater increases in SBP and DBP between 43 and 53 years were positively associated with WMHV at 69-71 years of age (increase in mean WMHV per 10 mm Hg greater SBP 7%, 95% CI 1-14, p=0·024; increase in mean WMHV per 10 mm Hg greater DBP 15%, 4-27, p=0·0057; increase in mean WMHV per one SD change in SBP 15%, 3-29, p=0·012; increase in mean WMHV per 1 SD change in DBP 15%, 3-30, p=0·017). Higher DBP at 43 years of age was associated with smaller whole-brain volume at 69-71 years of age (-6·9 mL per 10 mm Hg greater DBP, -11·9 to -1·9, p=0·0068), as were greater increases in DBP between 36 and 43 years of age (-6·5 mL per 1 SD change, -11·1 to -1·9, p=0·0054). Greater increases in SBP between 36 and 43 years of age were associated with smaller hippocampal volumes at 69-71 years of age (-0·03 mL per 1 SD change, -0·06 to -0·001, p=0·043). Neither absolute blood pressure nor change in blood pressure predicted amyloid-β status or PACC score at 69-71 years of age.
INTERPRETATION
High and increasing blood pressure from early adulthood into midlife seems to be associated with increased WMHV and smaller brain volumes at 69-71 years of age. We found no evidence that blood pressure affected cognition or cerebral amyloid-β load at this age. Blood pressure monitoring and interventions might need to start around 40 years of age to maximise late-life brain health.
FUNDING
Alzheimer's Research UK, Medical Research Council, Dementias Platform UK, Wellcome Trust, Brain Research UK, Wolfson Foundation, Weston Brain Institute, Avid Radiopharmaceuticals.
Identifiants
pubmed: 31444142
pii: S1474-4422(19)30228-5
doi: 10.1016/S1474-4422(19)30228-5
pmc: PMC6744368
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
942-952Subventions
Organisme : British Heart Foundation
ID : PG/17/90/33415
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00019/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00019/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/2
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00019/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/3
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Neurology. 1998 Jul;51(1):319-20
pubmed: 9674838
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Med Image Anal. 2013 Aug;17(6):671-84
pubmed: 23510558
BMC Res Notes. 2018 Dec 13;11(1):885
pubmed: 30545411
JAMA Neurol. 2013 May;70(5):600-6
pubmed: 23553344
Circulation. 1997 Jul 1;96(1):308-15
pubmed: 9236450
Clin Neuropsychol. 2014;28(5):771-85
pubmed: 24815535
Int J Epidemiol. 2011 Feb;40(1):e1-9
pubmed: 21345808
J Am Heart Assoc. 2018 Aug 7;7(15):e009578
pubmed: 30371241
Ann Neurol. 2011 Nov;70(5):774-80
pubmed: 22162060
Eur Heart J. 2014 Dec 7;35(46):3287-95
pubmed: 25246483
Am J Epidemiol. 2006 Jul 1;164(1):85-94
pubmed: 16675536
Int J Hypertens. 2011;2011:478710
pubmed: 21811670
BMC Neurol. 2017 Apr 18;17(1):75
pubmed: 28420323
JAMA Neurol. 2015 May;72(5):546-53
pubmed: 25822631
JAMA. 1995 Dec 20;274(23):1846-51
pubmed: 7500533
Neuroimage. 2015 Jan 1;104:366-72
pubmed: 25255942
Neurology. 2014 Jun 17;82(24):2187-95
pubmed: 24898928
Neurology. 2017 Dec 12;89(24):2447-2454
pubmed: 29117954
Neurobiol Aging. 2012 Apr;33(4):827.e11-9
pubmed: 21821316
Int J Epidemiol. 2016 Aug;45(4):1091-1102
pubmed: 27413103
IEEE Trans Med Imaging. 2015 Oct;34(10):2079-102
pubmed: 25850086
JAMA. 2017 Apr 11;317(14):1443-1450
pubmed: 28399252
J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1299-306
pubmed: 26294005
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Hypertension. 2016 Dec;68(6):e67-e94
pubmed: 27977393
J Hypertens. 2013 Aug;31(8):1502-16
pubmed: 23811995
Alzheimers Dement. 2016 Aug;12(8):890-9
pubmed: 27139841
Stroke. 2010 Jan;41(1):3-8
pubmed: 19926835
Neurology. 2018 Oct 16;91(16):e1479-e1486
pubmed: 30232248
Psychoneuroendocrinology. 2014 Sep;47:189-98
pubmed: 25001968
JAMA Neurol. 2017 Jun 1;74(6):718-726
pubmed: 28418521
Neuroimage. 2011 Apr 1;55(3):1091-108
pubmed: 21195780
JAMA. 2019 Feb 12;321(6):553-561
pubmed: 30688979
Neurology. 2011 Aug 2;77(5):461-8
pubmed: 21810696